USCA RIA’s Lexicon Pharmaceuticals LXRX Stock Holding History

USCA RIA’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-5,714	Closed	-$87K	–	254
2013 Q2	$87K	Buy	+5,714	New	+$86.8K	0.04%	230

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

USCA RIA's LXRX Position: Q3 2013 in Review

USCA RIA sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2013, closing a stake of 5,714 shares — an estimated $87K sold.

USCA RIA first reported a position in LXRX in Q2 2013 and held it in 1 quarter. The position peaked at $87K in Q2 2013. 102 funds tracked by Wall St. Rank hold LXRX as of Q3 2013.

USCA RIA reported no remaining Lexicon Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
USCA RIA sold 5,714 Lexicon Pharmaceuticals shares in Q3 2013, an estimated $87K.
USCA RIA first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 1 quarter.
USCA RIA's Lexicon Pharmaceuticals position peaked at $87K in Q2 2013.
102 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2013.

Based on USCA RIA's 13F filing for Q3 2013, filed 14 Nov 2013.